A-923573

N/A

Report date: 2026/05/14 20:00:28

NME

Base Information

Drug NameA-923573

Drug Alias NameA-923573.7A-923573

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsInsulin-like growth factor I receptor inhibitors

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Insulin-like growth factor I receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAbbott Laboratories

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbott Laboratories

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A